Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9%
Takeda Pharmaceutical Company Limited (TAK) reported a 40% decline in net profit for the first half, totaling 112.4 billion yen. Earnings per share fell to 70.45 yen from 117.11 yen. Core operating profit decreased by 11.2% to 639.2 billion yen, with core EPS at 279 yen compared to 310 yen. Revenue for the period was 2.22 trillion yen, down 6.9%. For the fiscal year ending March 31, 2026, the company anticipates basic EPS of 97.14 yen and revenue of 4.5 trillion yen.
Takeda Pharmaceutical Company Limited (TAK) reported first half net profit to owners of company of 112.4 billion yen, down 40.0% from prior year. Earnings per share was 70.45 yen compared to 117.11 yen. Core operating profit was 639.2 billion yen, down 11.2%. Core EPS was 279 yen compared to 310 yen. For the six-month period ended September 30, 2025, revenue was 2.22 trillion yen, down 6.9% from previous year.
For fiscal year ending March 31, 2026, the company expects: basic earnings per share of 97.14 yen, and revenue of 4.5 trillion yen.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
